

**Shionogi establishes Ezose Sciences, a jointly-owned US venture company
providing serum glycan analysis services**

February 23, 2009 -- Shionogi & Co., Ltd. (Head Office: Osaka; President: Isao Teshirogi; hereafter "Shionogi") today announced that its Board has decided to establish "Ezose Sciences, Inc.", a jointly owned venture company with Sumitomo Bakelite Co., Ltd. (Head Office: Tokyo; President: Tomitaro Ogawa; hereafter "Sumitomo Bakelite"). The purpose of the company will be to provide various services applying novel technologies developed by Shionogi, Hokkaido University and Sumitomo Bakelite, which enable the analysis of serum glycans (sugar chains) and discovery of novel biomarkers.

Shionogi is aggressively preparing for long-term growth as a pharmaceutical company by strengthening its global organization, as outlined in the second medium-term business plan (April, 2005-March, 2010). With respect to research and development, Shionogi aims to steadily build a base for full-scale overseas development, with a particular emphasis on expanding infrastructure in the United States.

In May 2008, Shionogi established a wholly-owned research facility, "Shionogi Innovation Center for Drug Discovery", on the campus of Hokkaido University, in order to share expertise and discover globally competitive drug candidates, as well as educate personnel and foster industrial-academic collaboration. Ezose Sciences will further refine and apply novel serum glycan analysis technologies which have been developed by Hokkaido University as a superior drug and biomarker discovery technology platform, as well as novel glycoblotting materials manufactured by Sumitomo Bakelite. One of the objectives for Ezose Sciences will be to make these novel glycan analysis technologies recognized as a worldwide standard that can be applied to strengthen and streamline the pharmaceutical R&D process as well as enhance probability of success.

Overview of the Ezose Sciences, Inc. (currently planned):

Corporate Name:	Ezose Sciences, Inc.
The main business:	Novel glycan analysis services
Date of Establishment:	End of February 2009

Date of Operations Initiation: June 2009

Address: New Jersey, U.S.A.

Initial Capitalization: 9 million USD (Shionogi 87%, Sumitomo Bakelite 13%)

Number of Staff: Initially approximately 10

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For further information:

Shionogi & Co., Ltd., Corporate Communications Department

Tel: +81-6-6209-7885 Fax: +81-6-6229-9596